目的 分析2型糖尿病应用达格列净治疗在脂代谢和内脏脂肪方面的影响。方法 回顾性分析吉林省松原市中西医结合医院2023年5月至2024年5月接诊的80例2型糖尿病患者,根据治疗方式的不同分为两组,各40例,对照组予以常规治疗,研究组在其基础上给予达格列净治疗,检查两组血糖指标、脂代谢指标、内脏脂肪指标。结果 治疗后两组糖化血红蛋白、空腹血糖、餐后2 h血糖均低于同组治疗前,且研究组低于对照组（P<0.05）。治疗后两组甘油三酯、总胆固醇、低密度脂蛋白胆固醇均低于同组治疗前,且研究组低于对照组（P<0.05）。治疗后两组内脏脂肪指数、内脏脂肪素、内脏脂肪组织来源的丝氨酸蛋白酶抑制剂均低于同组治疗前,且研究组低于对照组（P<0.05）。结论 2型糖尿病应用达格列净治疗可以改善脂代谢情况,降低内脏脂肪,应用价值高。

Objective To analyze the effects of dagliflozin treatment applied to type 2 diabetes mellitus in terms of lipid metabolism and visceral fat. Methods A retrospective analysis of 80 patients with type 2 diabetes treated from May 2023 to Songyuan Hospital of Integrated Chinese and Western Medicine, Jilin Province in May 2024, were divided into two groups with 40 cases each groups according to the different treatment methods. The reference group received conventional treatment, and the study group received dagliflozin treatment, and examined the two groups' blood glucose index, lipid metabolism index and visceral fat index. Results After the treatment, glycosylated hemoglobin, fasting blood glucose and 2 hours postprandial blood glucose were lower than before the same group, and the study group was lower than the reference group (P<0.05). After treatment, triglycerides, total cholesterol and LDL cholesterol were lower than before the same group, and the study group was lower than the reference group (P<0.05). After treatment, visceral fat index, visceral fatin, visceral adipose tissue-derived serine protease inhibitors were lower than before treatment in the same group, and the study group was lower than the reference group (P<0.05). Conclusions Dagagliflozin treatment for type 2 diabetes can improve fat metabolism, reduce visceral fat and have high application value.